Getting ahead of headache

After several false starts, investments in CGRP inhibitors are bearing fruit in the clinic - if not exactly the prize pumpkins once hoped for from the class. Still, if the sponsors developing these products can convince payers to reimburse them, anti-CGRP mAbs could grab a slice of a potentially large market.

So far, three mAbs in advanced clinical testing that target calcitonin gene-related peptide and one targeting its receptor appear to offer efficacy equal to or modestly better than generics, without the side effects that hinder generic use...